Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 701–800 of 2,656
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Kristensen, D. K., Mose, F. H., Buus, N. H., Duus, C. L., Mårup, F. H., Bech, J. N., & Nielsen, S. F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16097 · Cited by 10
Bellos, I., Marinaki, S., Λάγιου, Π., & Benetou, V. (2024) · Biomolecules · doi:10.3390/biom15010039 · Cited by 12
Therapeutic Consequences and Prognostic Impact of Multimorbidity in Heart Failure: Time to Act
Bánfi‐Bacsárdi, F., Kazay, Á., Gergely, T. G., Forrai, Z., Füzesi, T. P., Hanuska, L. F., Schäffer, P. P., Pilecky, D., Vámos, M., Vértes, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm14010139 · Cited by 13
“Besides HF, the beneficial effect of SGLT2i dapa-and empagliflozin in diabetes and chronic kidney disease are well established (DECLARE-TIMI 58 [35], EMPA-REG OUTCOME [34], DAPA-CKD [67], EMPA-KIDNEY [33]).”
Sharma, N., Liu, W., Tsai, X.-Q. E., Wang, Z., Outtrim, C., Tang, A., Pieper, M. P., Reinhart, G. A., & Huang, Y. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00254.2024 · Cited by 12
Scardini, P. G., Katsuyama, E. S., Prata, A. A., Fernandes, J. M., Fukunaga, C. K., Neto, W. F., Coan, A. C. C., de Andrade, N. M., da Silva, A., Pinheiro, R. P. S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02540-4 · Cited by 13
Integrated primary and secondary care optimizes the management of people with CKD—the LUCID project
Major, R., Lakhani, N., Ahmed, Y., Atkin, J., Baines, R. J., Balment, R., Cheung, C. K., Graham-Brown, M. P. M., Ellwood, C. N., Harding, L., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf049 · Cited by 10
Shah, S., Mushahid, H., Salman, A., Farhan, S. H., Latif, F., Siddiqi, R. L., Nashwan, A. J., Abramov, D., & Minhas, A. M. K. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01183-8 · Cited by 13
John, E. E., Travlos, C. K., Luu, J., Lemay, S., Suri, R. S., & Mavrakanas, T. A. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000693 · Cited by 11
Noiri, J., Fujimoto, W., Takemoto, M., Kuroda, K., Yamashita, S., Imanishi, J., Iwasaki, M., Todoroki, T., Okuda, M., Nagao, M., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0002 · Cited by 12
“29 Thus, SGLT2 inhibitors, if administered with appropriate monitoring, can be safe for Class 4 CKD patients.”
Innovative therapeutics for renoprotection: Where we are
Cortinovis, M., Perico, N., & Remuzzi, G. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100060 · Cited by 10
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 14
Elkeraie, A. F., Zyada, R. S., Elrggal, M. E., & Elrggal, M. E. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03508-1 · Cited by 12
Bedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Abdelrahman, A. M., Awad, A. S., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040956 · Cited by 14
Moady, G., Yakubovich, I., & Atar, S. (2024) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484241252474 · Cited by 10
Fortes, R., Neves, I. C., Costa, J. S., & Oliveira, S. K. E. D. L. (2024) · Editora Conhecimento Livre eBooks · doi:10.37423/240408916 · Cited by 10
Varghese, L., Chang, P. W., Juntarasiripas, S., et al. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2368990 · Cited by 10
SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
Jaswaney, R., Sokoloff, S., Rakita, V., & Rubin, D. J. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.23093 · Cited by 15
Mapelli, M., Mantegazza, V., Ferrari, C., Cimino, R., Maragna, R., Pontone, G., Pepi, M., & Agostoni, P. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14344 · Cited by 9
Hsu, C., Hsuan, C., Liao, D., Chang, J. K.-J., Chang, A. J.-W., Hee, S., Lee, H.-L., & Teng, S. I. F. (2023) · Life · doi:10.3390/life13041024 · Cited by 14
“There were, however, no significant between-group differences with respect to the composite outcome of HHF or CV death [26].”
ResultDid you know how SGLT2 inhibitors protect the kidney?
Layton, A. T., & Vallon, V. (2023) · Acta Physiologica · doi:10.1111/apha.14011 · Cited by 12
“First, it lowers the delivery of NaCl to the macula densa, which activates tubuloglomerular feedback (TGF) and increases single nephron GFR (SNGFR).”
BackgroundInfluentialKani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Wasehuus, V. S., Smeijer, J. D., Ambery, P., Greasley, P. J., Wijkmark, E., Wheeler, D. C., Rossing, P. R., & Heerspink, H. J. L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16468 · Cited by 11
Developing a Protocol for Management of Euglycemic Diabetic Ketoacidosis
Cardona, Z., Friedman, J. G., Kamal, N., Oakes, D. J., Wallia, A., Aleppo, G., Brown, S., Makowski, C. T., Ritter, K., & Szmuilowicz, E. D. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01604-3 · Cited by 15
“Additionally, the EMPA-KIDNEY trial demonstrated reduced risk of progression of kidney disease in individuals with chronic kidney disease with use of SGLT2-i which ultimately led to FDA approval for use in chronic kidney disease regardless of diabetes status [ 19].”
Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease
Liang, F., Gui, L., Chen, K., Chen, J., He, J., & He, Y. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70086 · Cited by 14
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
Kobayashi, M., Bozkurt, B., Myhre, P. L., López‐Azor, J. C., Guzik, M., Iwanek, G., Baudry, G., Marcos, M. C., Miró, Ò., Dauw, J., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70079 · Cited by 11
Savonitto, S., Alpert, J. S., Thiele, H., Campo, G. C., Niccoli, G., Servi, S. D., Braunwald, E., & Granger, C. B. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf958 · Cited by 13
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge
Pradhan, N., & Dobre, M. A. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01172-5 · Cited by 16
“Originally developed to manage hyperglycemia in type 2 diabetes mellitus, the evidence for renoprotective effects of SGLT2i, continue to be re-affirmed through multiple rigorously designed clinical trials both in diabetic and nondiabetic individuals [26–28].”
Framework of Guidelines for Management of CKD in Asia
Pollock, C. A., Moon, J., Ha, L. P. N., Gojaseni, P., Ching, C. H., Gomez, L., Chan, T. M., Wu, M., Yeo, S. C., Nugroho, P., et al. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.12.010 · Cited by 15
Morales, J., & Palmer, B. F. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2316572 · Cited by 9
“In the EMPA-KIDNEY trial (NCT03594110) conducted in a diverse group of CKD patients at risk for disease progression, treatment with empagliflozin was associated with a reduced risk of progression of kidney disease or CV-related mortality compared to placebo [34].”
BackgroundCastoldi, G., Carletti, R., Barzaghi, F., Meani, M., Zatti, G., Perseghin, G., Gioia, C. R. T. D., & Zerbini, G. (2024) · Pharmaceuticals · doi:10.3390/ph17030362 · Cited by 10
Wagner, B. R., & Rao, P. S. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001002 · Cited by 10
Svensson, M. K. E., Tangri, N., Bodegård, J., Eryd, S. A., Thuresson, M., & Sofue, T. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae100 · Cited by 12
Murphy, D. P., Wolfson, J. A., Reule, S. A., Johansen, K. L., Ishani, A., & Drawz, P. E. (2024) · Kidney International · doi:10.1016/j.kint.2024.03.026 · Cited by 14
SGLT2 Inhibitors and Uric Acid Homeostasis
Zapf, A. M., & Woodward, O. M. (2024) · Gout Urate and Crystal Deposition Disease · doi:10.3390/gucdd2020014 · Cited by 10
“The recent EMPA-KIDNEY trial tested this very question [72].”
BackgroundInfluentialBerrio, E. M., de la Flor, J. C., Segura, M. A., Rodríguez-Doyágüez, P., Martínez-Calero, A., Zamora, R., Terrones, M. C., Yuste-Lozano, C., García, M. D. S. D. L. N., Iglesias, J. N., et al. (2024) · Medicina · doi:10.3390/medicina60081198 · Cited by 14
Clinical trial designs of emerging therapies for diabetic kidney disease (DKD)
Singh, A. K., Farag, Y. M. K., Zheng, Z., & Bakris, G. L. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2377529 · Cited by 10
“EMPA-KIDNEY, DAPA-CKD, and CREDENCE are the major landmark clinical trials of SGLT2i, which examined the effects of empagliflozin, dapagliflozin, and canagliflozin, respectively [4– 6].”
InfluentialVernstrøm, L., Gullaksen, S., Sørensen, S. S., Ringgaard, S., Laustsen, C., Birn, H., Funck, K. L., Laugesen, E., & Poulsen, P. L. (2024) · Diabetologia · doi:10.1007/s00125-024-06228-y · Cited by 11
Berezina, T. A., Berezin, O. O., Hoppe, U. C., Lichtenauer, M., & Berezin, A. Е. (2024) · Diagnostics · doi:10.3390/diagnostics14161728 · Cited by 11
Long-term renal survival in patients with IgA nephropathy: a systematic review
Zhang, H., Ren, S., Hu, J., & Li, G. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2394636 · Cited by 13
“SGlt2 inhibition in DAPA-cKD and eMPA-KiDNeY trials clearly demonstrated renal protection in non-diabetic chronic kidney disease [27,28].”
BackgroundNeumiller, J. J., Herrin, J. S., SWARNA, K. S., Polley, E. C., Galindo, R. J., Umpierrez, G. E., Deng, Y., Ross, J. S., Mickelson, M. M., & McCoy, R. G. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000587 · Cited by 13
Randomized, Placebo-Controlled Trial on the Renal and Systemic Hemodynamic Effects of Empagliflozin
Nielsen, S. F., Duus, C. L., Buus, N. H., Bech, J. N., & Mose, F. H. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.10.019 · Cited by 14
Ostrominski, J. W., Lassen, M. C. H., Claggett, B. L., Miao, Z. M., Inzucchi, S. E., Docherty, K. F., Desai, A. S., Jhund, P. S., Køber, L., Ponikowski, P. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae780 · Cited by 13
Tsatsaronis, A., Tiong, M. K. D., Nicholls, K., & Ruderman, I. (2024) · Internal Medicine Journal · doi:10.1111/imj.16603 · Cited by 11
Kloza, M., Krzyżewska, A., Kozłowska, H., Budziak, S., & Baranowska‐Kuczko, M. (2025) · Cells · doi:10.3390/cells14070507 · Cited by 11
“It also has slightly stronger nephroprotective effects than other SGLT2 inhibitors, the best hemodynamic profile, and a lower risk of side effects [2,3,6] and has been shown to exert beneficial effects in vasculoprotective effect in different phases of diabetes disease progression, including in…”
Lee, Y., Wu, L., Wu, V., & Chang, C. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.03.016 · Cited by 16
Kostev, K., Lang, M., Tröbs, S., Urbisch, S., & Gabler, M. (2025) · Medicina · doi:10.3390/medicina61050843 · Cited by 16
Skaarup, K. G., Johansen, N. D., Brandi, L., Lindhardt, M. K., Bech, J. N., Svensson, M. H. S., Kristensen, T., Thuesen, A. D., Knudsen, M. G., Kampmann, J. D., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.075403 · Cited by 12
German, J., Yang, Z., Urbut, S., Vartiainen, P., FinnGen, Gana, A., Natarajan, P., Patorno, E., Kutalik, Z., Philippakis, A., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02229-8 · Cited by 16
The use of SGLT2 inhibitors in older people: What is important?
Armentaro, G., Maio, R., Bencivenga, L., Okoye, C., Severini, G., Cassano, V., Zanobbi, V., Condoleo, V., Bellelli, G., Rengo, G., et al. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-03156-8 · Cited by 10
Chronic Kidney Disease in Patients With Heart Failure With a Preserved Ejection Fraction
Packer, M., Testani, J. M., Butler, J., Zannad, F. M., Lam, C. S. P., Vaduganathan, M., Fang, J. C., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.086 · Cited by 15
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY
Malijan, G. M., Sardell, R. J., Staplin, N., Devuyst, O., Chapman, D., Hill, M., Nägele, N., Moffat, S., Wijayaratne, D. R., Donovan, K., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.004 · Cited by 14
Treatment of membranous nephropathy: Perspectives on current and future therapies
Shah, M., DeLaat, A., & Cavanaugh, C. J. (2023) · Frontiers in Nephrology · doi:10.3389/fneph.2023.1110355 · Cited by 9
SGLT2 inhibitors: new kids on the block to control hyperkalemia
Gabai, P., & Fouque, D. P. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad026 · Cited by 9
Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
Colbert, G. B., Madariaga, H. M., Gaddy, A. R., Elrggal, M. E., & Lerma, E. V. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s398163 · Cited by 12
Packer, M., Siddiqi, T. J., & Butler, J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad158 · Cited by 9
Lv, J., Guo, L., Wang, R., & Chen, J. (2023) · Kidney Diseases · doi:10.1159/000530395 · Cited by 16
Piccirillo, F., Liporace, P., Nusca, A., Nafisio, V., Corlianò, A., Magarò, F., Incalzi, R. A., Ussia, G. P., & Grigioni, F. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10060236 · Cited by 12
Martínez, J. J. G., Ferreira-Ocampo, P. J., Sanz-Pastor, A. G., Cárdenas‐Salas, J., Antón-Bravo, T., Brito-Sanfiel, M. Á., & Ruiz, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134248 · Cited by 9
“Moreover, emerging evidence suggests that these benefits extend to non-T2DM patients with HF (the EMPEROR-PRESERVED, EMPEROR REDUCED, DAPA-HF, and DELIVER trials) [3,4] or CKD (the DAPA-CKD and EMPA-KIDNEY trials) [3,5].”
BackgroundAutoimmune liver diseases and diabetes
Jensen, A. H., Ytting, H., Winther‐Sørensen, M., Burisch, J. M., Bergquist, A. M., Gluud, L. L., & Albrechtsen, N. J. W. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002594 · Cited by 12
Babazono, T., Hanai, K., Yokoyama, Y., & Uchiyama, K. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02380-8 · Cited by 9
“…placebo-controlled double-blind clinical studies evaluating medications for CKD in diabetes, such as mineralocorticoid receptor antagonists (MRAs) and sodium glucose co-transporter 2 (SGLT2) inhibitors demonstrated correlations between changes in UACR and the incidence of kidney events [13–15].”
BackgroundPlasma Serotonin and Cardiovascular Outcomes in Chronic Kidney Disease
Edmonston, D. L., Isakova, T., Wolf, M. S., Appel, L. J., Chen, J., Feldman, H. I., Cohen, D. L., Go, A. S., Lash, J. P., Nelson, R. G., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.029785 · Cited by 13
Chipayo-Gonzales, D., Shabbir, A., Vergara-Uzcategui, C. E., y, L. N.-F., Jiménez‐Quevedo, P., Gonzalo, N., Nuñez-Gil, I. J., Mejía-Rentería, H. D., Macaya‐Ten, F., Tirado‐Conte, G., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01454-w · Cited by 11
“The renal benefits [6, 14, 15] of this pharmaceutical group were confirmed in our study, with a trend towards reducing the development of renal failure in the final follow-up independently of the revascularization strategy and the use of contrast during percutaneous coronary intervention or extracorporeal circulation…”
BackgroundResultExploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
Novel pharmacological interventions for diabetic kidney disease
Tan, S. K., Pinzón-Cortés, J. A., & Cooper, M. E. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000935 · Cited by 10
Yoshihara, F., Imazu, M., Sakuma, I., Hiroi, Y., Hara, H., Okazaki, O., Ishiguro, C., Izumi, C., Noguchi, T., Shiraiwa, T., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102334 · Cited by 11
Expanding options of supportive care in IgA nephropathy
Maixnerová, D., Hartinger, J. M., & Tesař, V. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad201 · Cited by 11
“The EMPA-KIDNEY trial confirmed that treatment with empagliflozin ( SGLT2i ) led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo [ 33 ].”
MethodIgA Nephropathy: Beyond the Half-Century
Shimizu, Y., Tomino, Y., & Suzuki, Y. (2023) · Medicina · doi:10.3390/medicina60010054 · Cited by 12
Zeitler, E. M., Glenn, D. A., Hu, Y., Falk, R. J., Hogan, S. L., Mottl, A. K., Gharavi, L., Greenbaum, L., Rheault, M. N., Smoyer, W. E., et al. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.03.020 · Cited by 11
Bodini, S., Pieralice, S., D’Onofrio, L., Mignogna, C., Coraggio, L., Amendolara, R., Risi, R., Salducci, M., Buzzetti, R., & Maddaloni, E. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.009 · Cited by 13
A Review of Sotagliflozin: The First Dual SGLT-1/2 Inhibitor
Siddiqui, Z., Rasouli, N., Felder, E., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000760 · Cited by 10
New Landmarks to Slow the Progression of Chronic Kidney Disease
Simonini, M., & Vezzoli, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010002 · Cited by 9
“SGLT2 inhibitors have been shown to prevent CKD progression in patients with diabetes at high cardiovascular risk [21,22], and recent findings indicate that they may also exert this effect in non-diabetic CKD [23].”
BackgroundKeidai, Y., Yoshiji, S., Hasebe, M., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., & Inagaki, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15122 · Cited by 13
Hirota, Y., Kakei, Y., Imai, J., Katagiri, H., Ebihara, K., Wada, J., Suzuki, J., Urakami, T., Omori, T., & Ogawa, W. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01526-x · Cited by 10
Medical Nutrition Therapy for Chronic Kidney Disease: Low Access and Utilization
Lee, P., Kouba, J., Jimenez, E. Y., & Kramer, H. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.12.001 · Cited by 11
GLP ‐1 agonists and SGLT ‐2 inhibitors in adults with sickle cell disease
Sun, R., Srivastava, A., Derebail, V. K., Han, J., Molokie, R. E., Gordeuk, V. R., & Saraf, S. L. (2024) · American Journal of Hematology · doi:10.1002/ajh.27348 · Cited by 8
Management and Pharmacological Treatment of Peripheral Arterial Disease
Leatham, S. J., Winckel, K., & Guzman, K. R. D. (2024) · Journal of Pharmacy Practice · doi:10.1177/08971900241250084 · Cited by 10
RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
Is GFR decline induced by SGLT2 inhibitor of clinical importance?
Günes-Altan, M., Bosch, A., Striepe, K., Bramlage, P., Schiffer, M., Schmieder, R. E., & Kannenkeril, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02223-0 · Cited by 12
“Sodium-glucose-cotransporter-2 (SGLT2) inhibitors have demonstrated remarkable cardiovascular (CV) and renal benefits beyond glycemic control in several trials and emerged as therapeutic agents in the treatment of heart failure and chronic kidney disease [1–10].”
BackgroundSGLT2i treatment during AKI and its association with major adverse kidney events
Alcantar-Vallin, L., Zaragoza, J. J., Díaz-Villavicencio, B., Hernández-Morales, K., Camacho-Guerrero, J. R., Pérez-Venegas, M. A., Carmona, E. J., Gonzalez, A. N. O., Murguía-Soto, C., Chávez-Alonso, G., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1356991 · Cited by 10
State-of-Art Therapeutics in IgA Nephropathy
Mathur, M., Sahay, M., Pereira, B. J. G., & Rizk, D. V. (2024) · Indian Journal of Nephrology · doi:10.25259/ijn_319_23 · Cited by 8
Obrador, G. T., Álvarez-Estévez, G., Bellorín-Font, E., Bonanno-Hidalgo, C., Clavero, R., Correa‐Rotter, R., Diná-Batlle, E., Morales, L., Orozco, R., Ortiz, F., et al. (2024) · Nefrología Latinoamericana · doi:10.24875/nefro.m24000037 · Cited by 16
Lamb, E. J., Barratt, J., Brettell, E. A., Cockwell, P., Dalton, R. N., Deeks, J. J., Eaglestone, G., Pellatt‐Higgins, T., Kalra, P. A., Khunti, K., et al. (2024) · Health Technology Assessment · doi:10.3310/hyhn1078 · Cited by 17
Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan
Maruyama, S., Tanaka, T., Akiyama, H., Hoshino, M., Inokuchi, S., Kaneko, S., Shimamoto, K., & Ozaki, A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae228 · Cited by 11
Clinical Phenotypes of Heart Failure Patients with Supranormal Ejection Fraction
Huang, L., Feng, J., Zhai, M., Huang, Y., Zhou, Q., Zhang, Y., & Zhang, J. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15021 · Cited by 10
Fabre, L., Pedregosa-Miguel, J. F., & Rangel, É. B. (2024) · Diabetology · doi:10.3390/diabetology5040030 · Cited by 8
Integrated multiomic analyses: An approach to improve understanding of diabetic kidney disease
Hill, C., McKnight, A. J., & Smyth, L. J. (2024) · Diabetic Medicine · doi:10.1111/dme.15447 · Cited by 11
“115,116 122 TABLE 2 Genes identified by Haukka et al. via WGS or WES to be associated with T1D-DKD and literature highlighting the biological plausibility of their involvement in DKD.”
Population Health Management and Guideline-Concordant Care in CKD
Weltman, M. R., Lavenburg, L.-M. U., Han, Z., Alghwiri, A. A., Mosslemi, M., Rollman, B. L., Fischer, G. S., Nolin, T. D., Yabes, J. G., & Jhamb, M. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000544 · Cited by 8
Zhu, H., Yang, C., Liu, X., Xu, X., Chen, Q., Fang, X., Huang, J., & Chen, T. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100920 · Cited by 8
“Evidence suggests that SGLT2 inhibitors not only lower the renal glucose threshold and improve volume status to alleviate heart failure but also reduce the risk of cardiovascular events, as confirmed in the DAPA-CKD [24], EMPA-KIDNEY [25], and CREDENCE [26] trials.”
Cao, M.-J., Liang, T., Xu, L., & Shi, F. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01547-x · Cited by 11
Siriwardana, A. N., Buizen, L., Jun, M., Kotwal, S. S., Arnott, C. G., Jardine, M., Levin, A., Heerspink, H. J. L., Charytan, D. M., Pollock, C. A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16190 · Cited by 9
Balancing Efficiency and Equity in Population-Wide CKD Screening
Cusick, M. M., Tisdale, R. L., Adams, A. S., Chertow, G. M., Owens, D. K., Salomon, J. A., & Goldhaber‐Fiebert, J. D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.4740 · Cited by 14
SGLT2 inhibitors and cardiovascular outcomes in patients with left ventricular assist devices
Pham, H. N., Ibrahim, R., Mee, X. C., Lim, G. K., Abdelnabi, M. H., Forst, B. J., Sarkis, P., Bcharah, G., Farina, J., Ayoub, C., et al. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.05.004 · Cited by 9
Beernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell‐McGee, A., Casillas, D. I., Driscoll, L. M., Greasley, P. J., Karlsson, C., Hammarstedt, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16478 · Cited by 11
Tsur, A., Leibowitz, G., Cohen, M. J., Cahn, A., & Pollack, R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16545 · Cited by 9
“7 Despite their well-established benefits in T2DM, the use of SGLT2i in type 1 diabetes mellitus (T1DM) has been approached with caution due to concerns over an increased risk of diabetic ketoacidosis (DKA), a rare but potentially life-threatening complication.”
Song, S. M., Kim, M., Jang, M., Kim, M., Lee, K. H., Jeon, J., Jin, S., Jang, H. R., Huh, W., & Lee, J. E. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.06.036 · Cited by 11
Management of Kidney Disease with Sickle Cell Disease
Abbasi, M., Srivastava, A., & Saraf, S. L. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000804 · Cited by 11
Mark, P. B., Sousa‐Amorim, E. D., Eriksson, A. L., Leonsson‐Zachrisson, M., Guzman, N. J., Miller, M. T., Jiang, Y., & Heerspink, H. J. L. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf119 · Cited by 12
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.